Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 892

Sort by

Sort Order Select

Journal Articles

Allogeneic Stem Cell Transplantation for High-Risk Multiple Myeloma

Rohan Vuppala, Charles Weeks, Mark Dalgetty, Danielle Bradshaw, Locke Johnson Bryan, Amany R. Keruakous, Anand Jillella, Vamsi K. Kota, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 7401.

https://doi.org/10.1182/blood-2024-211898

Published: 2024

Journal Articles

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

Jorge E. Cortes, Michael J. Mauro, Alexis Visotcky, Srinivas K Tantravahi, James E Thompson, Jay Yang, Arielle Baim, Yan Gao, Sonia Maldonado-Schmidt, Claire Olig, Kathryn E. Flynn, Jerald P. Radich, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 6601.

https://doi.org/10.1182/blood-2024-207884

Published: 2024

Journal Articles

Renal Adverse Events in Chronic Myeloid Leukemia: Can the Exposure to One TKI be the Culprit?

Reem Hajeomar, Maria Benkhadra, Rola Ghasoub, Jorge E. Cortes, Giuseppe Saglio, Awni Alshurafa, Nabeel Qasem, Islam Elkonaissi, Rasha Kaddoura, Mohamed A Yassin

Blood (2024) 144 (Supplement 1): 7920.

https://doi.org/10.1182/blood-2024-206775

Published: 2024

Journal Articles

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Shai O. Shimony, Heardley Murdock, Julia Keating, Christopher R. Reilly, Harrison K. Tsai, Christopher J. Gibson, Stefan Faderl, Tony Wagner, Nalina Dronamraju, Tara L. Lin, Ellen K. Ritchie, Thomas Prebet, Jorge E. Cortes, Geoffrey L. Uy, Jeffrey E Lancet, Donna S. Neuberg, Richard M. Stone, R. Coleman Lindsley

Blood (2024) 144 (Supplement 1): 60.

https://doi.org/10.1182/blood-2024-200413

Published: 2024

Journal Articles

Olutasidenib Alone or in Combination with Azacitidine in Patients with m IDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data

Jorge E. Cortes, Justin M. Watts, Eunice S. Wang, Jay Yang, Shira N. Dinner, Maria R. Baer, Gail J. Roboz, William B. Donnellan

Blood (2024) 144 (Supplement 1): 4600.

https://doi.org/10.1182/blood-2024-204039

Published: 2024

Journal Articles

Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3 -ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial

Blood (2024) 144 (Supplement 1): 848.

https://doi.org/10.1182/blood-2024-203303

Published: 2024

Journal Articles

Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP-CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses

Blood (2024) 144 (Supplement 1): 3151.

https://doi.org/10.1182/blood-2024-207139

Published: 2024

Journal Articles

Clinical Assessment of Cumulative Stress Via Allostatic Load in Chronic Myeloid Leukemia Patients: Implications for Treatment Outcomes

Marisol Miranda, Kellen Cristine Tjioe, Muhannad Sharara, Maloney Mckenzie, Amany R. Keruakous, Locke Johnson Bryan, Anand Jillella, Vamsi K. Kota, Avirup Guha, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 3160.

https://doi.org/10.1182/blood-2024-209114

Published: 2024

Journal Articles

Cardinal: A Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tern-701 in Chronic Myeloid Leukemia

Elias Jabbour, Delphine Rea, Jorge E. Cortes, Andreas Hochhaus, Timothy P Hughes, Dong-Wook Kim, Hagop M. Kantarjian, Leanne Holes, Emil T. Kuriakose, Michael J. Mauro

Blood (2024) 144 (Supplement 1): 6594.

https://doi.org/10.1182/blood-2024-204153

Published: 2024

Journal Articles

Management Milestones in Chronic Myeloid Leukemia Associated with Covid-19

Vasile Musteata, Daniel Coriu, Sr., Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 6587.

https://doi.org/10.1182/blood-2024-199932

Published: 2024

Journal Articles

Implications of the Chronic Stress Pathway in Acute Myeloid Leukemia

Kellen Cristine Tjioe, Adetutu Adeyemi, Emily Jemison, Marisol Miranda-Galvis, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 6094.

https://doi.org/10.1182/blood-2024-201758

Published: 2024

Journal Articles

Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)

Ehab L. Atallah, Moshe Y. Levy, Paul B. Koller, Koji Sasaki, Srinivas K Tantravahi, David Andorsky, Celesteann T Bremer, Joshua F Zeidner, Marlise R. Luskin, Reinhold Munker, Daisy Yang, Dramane Laine, John Sabo, Ennan Gu, Michael J. Mauro, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 479.

https://doi.org/10.1182/blood-2024-200717

Published: 2024

Journal Articles

Acute Myeloid Leukemia Clinical Presentation in Standard Practice: Analysis of 20-Year Real-World Data

Kellen Cristine Tjioe, Muhannad Sharara, Marisol Miranda, Mariko Tameishi, Danny Brandt, Thomas David Brown, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 5961.

https://doi.org/10.1182/blood-2024-210837

Published: 2024

Journal Articles

Financial Toxicity of FDA-Approved Hematologic Malignancy Drugs: An Epidemiological Analysis of Cost

Charles Weeks, Mahran Shoukier, Mark Dalgetty, Rohan Vuppala, Shreya Desai, Abigayle B Simon, Vamsi K. Kota, Locke Johnson Bryan, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 7578.

https://doi.org/10.1182/blood-2024-206129

Published: 2024

Journal Articles

Effectiveness of Olutasidenib Versus Ivosidenib in Patients with Mutated Isocitrate Dehydrogenase 1 Acute Myeloid Leukemia Who Are Relapsed or Refractory to Venetoclax: The 2102-HEM-101 Trial Versus a US Electronic Health Record-Based External Control Arm

Catherine E. Lai, Thomas P. Leahy, Alex Turner, Amber Thomassen, Lixia Wang, Aaron Sheppard, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 1525.

https://doi.org/10.1182/blood-2024-205601

Published: 2024

Journal Articles

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Blood (2024) 144 (Supplement 1): 2426.

https://doi.org/10.1182/blood-2024-207278

Published: 2024

Journal Articles

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Jorge E. Cortes, Andreas Hochhaus, Timothy P Hughes, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Jiri Mayer, Yeow Tee Goh, Philipp le Coutre, Gabriel Etienne, Naoto Takahashi, Inho Kim, David Andorsky, Ghayas C. Issa, Felice Bombaci, Shruti Kapoor, Rajendra Jinwal, Lillian Yau, Richard Larson

Blood (2024) 144 (Supplement 1): 475.

https://doi.org/10.1182/blood-2024-203757

Published: 2024

Journal Articles

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Blood (2024) 144 (Supplement 1): 3148.

https://doi.org/10.1182/blood-2024-207634

Published: 2024

Journal Articles

Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia

Blood (2024) 144 (Supplement 1): 993.

https://doi.org/10.1182/blood-2024-201881

Published: 2024

Journal Articles

Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive ( FLT3 -ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)

Mark J. Levis, Harry Erba, Pau Montesinos, Elzbieta Patkowska, Jorge E. Cortes, Herve Dombret, Alexander E. Perl, Sergio Amadori, Jianxiang Wang, Richard F. Schlenk, Li Liu, Yasser M. Mostafa Kamel, Karima Imadalou, Abderrahmane Laadem, Mikkael A. Sekeres, Kristy Burns

Blood (2024) 144 (Supplement 1): 2890.

https://doi.org/10.1182/blood-2024-207305

Published: 2024

NARROW

Allogeneic Stem Cell Transplantation for High-Risk Multiple Myeloma

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

Renal Adverse Events in Chronic Myeloid Leukemia: Can the Exposure to One TKI be the Culprit?

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Olutasidenib Alone or in Combination with Azacitidine in Patients with m IDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data

Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3 -ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial

Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP-CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses

Clinical Assessment of Cumulative Stress Via Allostatic Load in Chronic Myeloid Leukemia Patients: Implications for Treatment Outcomes

Cardinal: A Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tern-701 in Chronic Myeloid Leukemia

Management Milestones in Chronic Myeloid Leukemia Associated with Covid-19

Implications of the Chronic Stress Pathway in Acute Myeloid Leukemia

Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)

Acute Myeloid Leukemia Clinical Presentation in Standard Practice: Analysis of 20-Year Real-World Data

Financial Toxicity of FDA-Approved Hematologic Malignancy Drugs: An Epidemiological Analysis of Cost

Effectiveness of Olutasidenib Versus Ivosidenib in Patients with Mutated Isocitrate Dehydrogenase 1 Acute Myeloid Leukemia Who Are Relapsed or Refractory to Venetoclax: The 2102-HEM-101 Trial Versus a US Electronic Health Record-Based External Control Arm

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia

Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive ( FLT3 -ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only